---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000004"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:28:09.932391+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC reports ~$710M FY2022 total revenue (+30% YoY); guides FY2023 to $940M-$1B

## Summary
- FY2022 unaudited total revenue ~$710M; DMD franchise net product revenue $507M (Translarna $289M, Emflaza $218M).
- Evrysdi collaboration/royalty revenue ~$175M in 2022.
- FY2023 total revenue guidance $940M-$1B; DMD franchise net product revenue $545-$565M.
- Non-GAAP R&D and SG&A expense guided to $890-$940M; up to $80M milestone payments.
- Three registration-directed trial results expected in 2023: sepiapterin (PKU), vatiquinone (MDAS, FA); Upstaza BLA submission H1 2023.

## SEC filing metadata
- accession: 0001070081-23-000004
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000004/0001070081-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000004/tmb-20230109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000004
- JSON: https://secwatch.observer/filing/0001070081-23-000004.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000004.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported fiscal year ending December 31, 2022 results: revenue total unaudited net revenue of approximately $710 million. Guidance initiated.
  - Period: fiscal year ending December 31, 2022
  - Revenue: total unaudited net revenue of approximately $710 million
  - Guidance: initiated
  - Result: preliminary results
  source text: On January 9, 2023, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2022, including that the Company expects to report (i) total unaudited net revenue of approximately $710 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000004/0001070081-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.